Valuation: MicroPort NeuroScientific Corporation

Market Cap 3.93B 4.59B 585M 507M 479M 434M 814M 56.11B 820M 5.72B 2.2B 28.45B 2.2B 2.15B 90.73B P/E 2026 *
16.5x
P/E 2027 * 14.4x
Enterprise Value 3.93B 4.59B 585M 507M 479M 434M 814M 56.11B 820M 5.72B 2.2B 28.45B 2.2B 2.15B 90.73B EV / Sales 2026 *
4.49x
EV / Sales 2027 * 3.89x
Free-Float
58.56%
Yield 2026 *
2.46%
Yield 2027 * 2.75%
08-31 MicroPort NeuroScientific Corporation Announces Delay in the in Publication of 2026 Interim Results CI
07-30 MicroPort NeuroScientific Unit Stent System Enters Chinese Regulator's Special Review Procedure MT
06-03 MicroPort NeuroScientific Corporation Approves Final Dividend for the Year Ended 31 December 2025 CI
06-03 MicroPort NeuroScientific Corporation commences an Equity Buyback Plan for 58,503,480 shares, representing 10% of its issued share capital, under the authorization approved on June 3, 2026. CI
06-02 MicroPort NeuroScientific Corporation's Equity Buyback announced on April 28, 2026, has expired. CI
05-28 MicroPort NeuroScientific Partners With OYMotion on Brain-Computer Interface Technology; Shares Jump 5% MT
05-25 MicroPort Neuro Unit Wins US FDA Marketing Approval for Embolization System MT
05-25 Microport Neuroscientific says FDA approves Numentm Helia coil for marketing RE
04-28 MicroPort NeuroScientific Corporation commences an Equity Buyback Plan for 57,553,156 shares, representing 10% of its issued share capital., under the authorization approved on June 27, 2025. CI
04-28 Biodlink International Company Limited Announces Changes in Executives and Board Committee, Effective from 29 April 2026 CI
03-25 MicroPort NeuroScientific posts FY profit attributable RMB184.5 million RE
03-25 MicroPort NeuroScientific Corporation Proposes Final Ordinary Dividend for the Year Ended 31 December 2025, Payable on 21 August 2026 CI
03-25 MicroPort NeuroScientific Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 CI
1 day-3.19%
1 month-8.15%
3 months-13.94%
6 months-29.77%
Current year-25.97%
1 month 8
Extreme 8.005
8.95
Current year 8
Extreme 8.005
14.53
1 year 8
Extreme 8.005
14.6
3 years 6.21
Extreme 6.21
19.06
5 years 6.21
Extreme 6.21
26.8
10 years 6.21
Extreme 6.21
26.8
Manager TitleAgeSince
Chief Executive Officer 50 -
Director of Finance/CFO 48 2018-05-31
Chief Tech/Sci/R&D Officer 62 2023-12-31
Director TitleAgeSince
Director/Board Member 50 2020-11-01
Director/Board Member 61 2020-11-01
Director/Board Member 45 2021-11-18
Date Insider Type Main position Quantity % Market Cap. Importance
4/1/26 Other

Chief Executive Officer

247,000 0.0422%
3/31/26 Other 30,067 0.0051% -
5/6/25 Other

Director

139,000 0.0241%
Change 5-day change 1-year change 3-year change Capi.($)
-3.19%0.00%-39.80%-29.34% 584M
-0.13%+1.83%-25.35%-3.85% 108B
-1.05%-2.49%-26.16%-2.03% 11.89B
+0.34%-7.22%+112.90%+128.54% 10.09B
-0.11%-4.97%-54.68%-71.47% 3.97B
-0.20%-4.04%-29.36%+26.15% 2.36B
+0.38%+20.05%-7.60%-64.63% 2.15B
-0.88%-5.63% - - 1.84B
+0.07%-3.99%-23.31%-31.19% 1.5B
Average -0.53%-1.18%-11.67%-5.98% 15.83B
Weighted average by Cap. -0.19%-5.64%-16.17%+3.07%

Financials

2026 *2027 *
Net sales 874M 1.02B 130M 113M 107M 96.51M 181M 12.48B 182M 1.27B 489M 6.33B 489M 478M 20.19B 1.01B 1.18B 150M 130M 123M 111M 209M 14.41B 211M 1.47B 565M 7.31B 564M 552M 23.31B
Net income 238M 278M 35.44M 30.7M 29.03M 26.28M 49.32M 3.4B 49.7M 346M 133M 1.72B 133M 130M 5.5B 276M 322M 41.1M 35.6M 33.66M 30.48M 57.2M 3.94B 57.63M 402M 155M 2B 154M 151M 6.38B
Net Debt - -
Logo MicroPort NeuroScientific Corporation
MicroPort NeuroScientific Corp is a company mainly engaged in the research, development and manufacturing of neuro-interventional medical devices. The products cover three areas of cerebrovascular disease, including hemorrhagic stroke, cerebral atherosclerotic stenosis and acute ischemic stroke. The hemorrhagic stroke products mainly include NUMEN coil, NUMEN Silk three dimensional (3D) electronically detachable coil, Nufairy absorbable embolization coil and Tubridge flow-diverting stent. The intracranial atherosclerotic stenosis products mainly include APOLLO intracranial stent, Bridge vertebral artery drug-eluting stent (DES) and Diveer intracranial balloon dilatation catheter. The acute ischemic stroke products mainly include Neurohawk intracranial thrombectomy device, Tigertriever revascularization stent and WAVE-track intracranial aspiration catheter. The products also include auxiliary access devices such as Fastrack microcatheter and U-track intracranial support catheter.
Employees
-
Trader
-
Investor
Global
-
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
6.909CNY
Average target price
10.98CNY
Spread / Average Target
+58.89%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2172 Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!